Morgan Stanley starts Enliven Therapeutics at overweight
Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash
Morgan Stanley initiated coverage on Enliven Therapeutics with an overweight rating and a $70 price target, citing the company's strong cash position and its clinical-stage oncology drug ELVN-001. The stock trades at $46.21, up 200% year-to-date, with analyst targets ranging from $64 to $82. Enliven expects to start its pivotal Phase 3 ENABLE-2 trial in late 2026, with topline data in 2028-2029 and first revenues projected for 2030.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.